The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 03, 2026
Filed:
Nov. 20, 2020
Genentech, Inc., San Francisco, CA (US);
Ventana Medical Systems, Inc., Tucson, AZ (US);
National Cancer Center, Tokyo, JP;
Adrian E. Murillo, Tucson, AZ (US);
Hiro Nitta, Tucson, AZ (US);
Donald G. Munroe, Tucson, AZ (US);
Amy A. Lo, San Francisco, CA (US);
Takeshi Kuwata, Kashiwa, JP;
Akio Kaito, Kashiwa, JP;
Atsushi Ochiai, Kashiwa, JP;
GENENTECH, INC., South San Francisco, CA (US);
NATIONAL CANCER CENTER, Tokyo, JP;
VENTANA MEDICAL SYSTEMS, INC., Tucson, AZ (US);
Abstract
A method for predicting responsiveness to a HER2-directed therapy by assessing HER2 heterogeneity in a tumor includes contacting a sample of the tumor with a biomarker-specific reagent that specifically binds to HER2 protein and detecting HER2 protein in the sample, contacting the sample of the tumor with a first nucleic acid probe that specifically binds HER2 genomic DNA and detecting HER2 gene amplification status in the sample, contacting the sample of the tumor with a second nucleic acid probe that specifically binds HER2 RNA and detecting HER2 RNA status in the sample scoring the HER2 protein (IHC), HER2 gene (DISH), and HER2 RNA (RNA-ISH), predicting that the tumor is responsive to the HER2-directed therapy if the tumor reveals a first foci having a first score and a second score, in which the first score and the second score are not the same.